Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study

Dalia Zaafar,Heba M. A. Khalil,Gehad E. Elkhouly,Abanoub Selim Sedeky,Yasmine H. Ahmed,Mona G. Khalil,Yasmin Abo-zeid

DOI: https://doi.org/10.1007/s13346-024-01530-z

2024-03-03

Drug Delivery and Translational Research

Abstract:Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related deaths worldwide. Current treatment strategies include surgical resection, liver transplantation, liver-directed therapy, and systemic therapy. Sorafenib (Sor) is the first systemic drug authorized by the US Food and Drug Administration (FDA) for HCC treatment. Nevertheless, the conventional oral administration of Sor presents several limitations: poor solubility, low bioavailability, drug resistance development, and off-target tissue accumulation, leading to numerous adverse effects. Nano-emulsion, a nano-delivery system, is a viable carrier for poorly water-soluble drugs. It aims to enhance drug bioavailability, target organ accumulation, and reduce off-target tissue exposure, thus improving therapeutic outcomes while minimizing side effects. This study formulated Sor nano-emulsion (Sor NanoEm) using the homogenization technique. The resultant nano-emulsion was characterized by particle size (121.75 ± 12 nm), polydispersity index (PDI; 0.310), zeta potential (-12.33 ± 1.34 mV), viscosity (34,776 ± 3276 CPs), and pH (4.38 ± 0.3). Transmission Electron Microscopy exhibited spherical nano-droplets with no aggregation signs indicating stability. Furthermore, the encapsulation of Sor within the nano-emulsion sustained its release, potentially reducing the frequency of therapeutic doses. Cytotoxicity assessments on the HepG2 cell line revealed that Sor NanoEm had a significantly (P < 0.05) more potent cytotoxic effect compared to Sor suspension. Subsequent tests highlighted superior pharmacokinetic parameters and reduced dosage requirements of Sor NanoEm in mice. It exhibited an enhanced safety profile, particularly in behavior, brain, and liver, compared to its suspended form. These findings underscore the enhanced pharmacological and toxicological attributes of Sor Nano-emulsion, suggesting its potential utility in HCC treatment.

pharmacology & pharmacy,medicine, research & experimental

What problem does this paper attempt to address?

The paper aims to address the limitations of Sorafenib in the treatment of hepatocellular carcinoma (HCC), including poor solubility, low bioavailability, development of drug resistance, and non-specific effects leading to imprecise targeting of healthy and tumor tissues. By encapsulating Sorafenib into nanoemulsions, the researchers hope to improve the drug's bioavailability, enhance targeted accumulation in tumor tissues, and reduce exposure to non-target tissues, thereby increasing therapeutic efficacy while reducing side effects. The paper also explores the effects of this nanoemulsion on the HepG2 cell line both in vitro and in vivo, evaluating its cytotoxicity, pharmacokinetic parameters, and safety. Experimental results indicate that Sorafenib nanoemulsions exhibit stronger cytotoxicity and better pharmacokinetic properties compared to traditional suspensions, with fewer side effects. These findings provide a potential new approach for HCC treatment.

Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study

Preparation, Pharmacokinetics, Tissue Distribution and Antitumor Effect of Sorafenib-Incorporating Nanoparticles in Vivo.

In Vivo Biodistribution, Biocompatibility, and Efficacy of Sorafenib-Loaded Lipid-Based Nanosuspensions Evaluated Experimentally in Cancer

A Polymeric Nanoformulation Improves the Bioavailability and Efficacy of Sorafenib for Hepatocellular Carcinoma Therapy

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanoparticles

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies

Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate

Preparation and Evaluation of Folate-Decorated Human Serum Albumin Nanoparticles for the Targeted Delivery of Sorafenib to Enhance Antihepatocarcinoma Efficacy

Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy

Application of Box-Behnken Design for Formulation Optimization of Sorafenib loaded Nanoparticles Targeting to Liver Carcinoma: Ex-vivo Intestinal Permeation and Cytotoxicity Study.

Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.

Evaluation of the cytotoxic activity of sorafenib‐loaded camel milk casein nanoparticles against hepatocarcinoma cells

Sorafenib Encapsulated in Nanocarrier Functionalized with Glypican-3 Specific Peptide for Targeted Therapy of Hepatocellular Carcinoma.

Progress In Application Of Nanotechnology In Sorafenib

Preparation of Glutathione-Regulated Sorafenib Targeted Nanodrug Delivery System and Its Antihepatocellular Carcinoma Activity

Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects As Observed with Fundus Microcirculation Imaging.

Enhanced anticancer activity of silver doped zinc oxide magnetic nanocarrier loaded with sorafenib for hepatocellular carcinoma treatment

In Vitro And In Vivo Evaluation Of Redox-Responsive Sorafenib Carrier Nanomicelles Synthesized From Poly (Acryic Acid) -Cystamine Hydrochloride-D--Tocopherol Succinate

Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo